Copyright
©The Author(s) 2017.
World J Diabetes. Jun 15, 2017; 8(6): 270-277
Published online Jun 15, 2017. doi: 10.4239/wjd.v8.i6.270
Published online Jun 15, 2017. doi: 10.4239/wjd.v8.i6.270
Agent | Glucose-lowering efficacy | Other favorable effects | Effect on ischemic stroke |
Metformin | High | Weight loss | Decrease |
Sulfonylureas | High | (-) | No effect |
Thiazolidinediones Pioglitazone | High | Reduction in triglyceride levels | Might reduce the risk of recurrent stroke |
DPP-4 inhibitors (1) Alogliptin, saxagliptin, sitagliptin (2) Linagliptin | Moderate | None | No effect Reduction (?) |
GLP-1 agonists (1) Liraglutide, lixisenatide (2) Semaglutide | High | Weight loss and blood pressure reduction | No effect Reduction |
SGLT-2 inhibitors Empagliflozin | Moderate | Weight loss and blood pressure reduction | No effect |
- Citation: Avgerinos K, Tziomalos K. Effects of glucose-lowering agents on ischemic stroke. World J Diabetes 2017; 8(6): 270-277
- URL: https://www.wjgnet.com/1948-9358/full/v8/i6/270.htm
- DOI: https://dx.doi.org/10.4239/wjd.v8.i6.270